(Xinhua-China) Israel's Teva Pharmaceutical Industries announced on Saturday that it would begin marketing Ajovy, a preventive drug against migraine, after it received approval from the U.S. FDA. Ajovy is the first drug for migraine that allows one injection for three months, compared with a U.S.-made drug that is injected monthly.
2018-09-17 00:00:00Full ArticleBACK Visit the Daily Alert Archive